Skip to search formSkip to main contentSkip to account menu

LY2090314

Known as: 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione, LY 2090314, GSK-3 Inhibitor LY2090314 
An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.
2018
2018
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have… 
2017
2017
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
The SCLC combination screen examined a 9‐point concentration response of 180 third agents, alone and in combination with… 
Highly Cited
2016
Highly Cited
2016
Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
Highly Cited
2016
Highly Cited
2016
A unique type of GSK-3 inhibitor brings new opportunities to the clinic
A substrate peptide that the kinase GSK-3 converts into its own inhibitor improves symptoms and cognitive function in an… 
Highly Cited
2015
Highly Cited
2015
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3
It has previously been observed that a loss of β-catenin expression occurs with melanoma progression and that nuclear β-catenin… 
Highly Cited
2015
Highly Cited
2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed…
SummaryPurpose LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when… 
2013
2013
Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low…
LY2090314 (3-[9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3… 
Highly Cited
2011
Highly Cited
2011
Deconstructing GSK-3: The Fine Regulation of Its Activity
Glycogen synthase kinase-3 (GSK-3) unique position in modulating the function of a diverse series of proteins in combination with… 
Highly Cited
2000
Highly Cited
2000
Two Different Signal Transduction Pathways Are Implicated in the Regulation of Initiation Factor 2B Activity in Insulin-like Growth Factor-1-stimulated Neuronal Cells*
Eukaryotic initiation factor eIF-2B plays an important role in translation regulation and has been suggested to be implicated in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)